Boston Type 1 Keratoprosthesis: Updated Perspectives

Manachai Nonpassopon,1,2 Muanploy Niparugs,2,3 Maria Soledad Cortina2 1Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; 3Department of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nonpassopon M, Niparugs M, Cortina MS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	boston keratoprosthesis corneal transplantation limbal stem cell deficiency Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d5857e8813e6450bbcef3a045b39cf13
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d5857e8813e6450bbcef3a045b39cf13
record_format	dspace
spelling	oai:doaj.org-article:d5857e8813e6450bbcef3a045b39cf132021-12-02T09:54:25ZBoston Type 1 Keratoprosthesis: Updated Perspectives1177-5483https://doaj.org/article/d5857e8813e6450bbcef3a045b39cf132020-04-01T00:00:00Zhttps://www.dovepress.com/boston-type-1-keratoprosthesis-updated-perspectives-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Manachai Nonpassopon,1,2 Muanploy Niparugs,2,3 Maria Soledad Cortina2 1Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; 3Department of Ophthalmology, Faculty of Medicine, Chaing Mai University, Chaing Mai, ThailandCorrespondence: Maria Soledad CortinaDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1855 W. Taylor Street, M/C 648, Chicago, IL 60612, USATel +1 312 996-6590Email mcortina@uic.eduAbstract: The use of Boston type 1 keratoprosthesis (BKPro) has significantly increased worldwide. It is no longer considered a procedure of last resort but a reasonable option for patients with otherwise poor prognosis for a traditional penetrating keratoplasty. BKPro was approved by the Food and Drug Administration in 1992 for bilateral severe corneal blindness due to multiple corneal transplant failure. Over the years, indications have extended beyond recurrent immunologic rejection to include other conditions such as chemical injury and other causes of bilateral limbal stem cell deficiency, extensive corneal neovascularization, neurotrophic corneas and hypotony, among others. Numerous advances in the design of the BKPro, improvement of preoperative, intraoperative and postoperative management have resulted in favorable outcomes and a reduction in postoperative complications. Accordingly, many studies have shown that implantation of this device is highly effective in restoring vision with very good short-term outcomes. However, due to the lifetime risk of sight-threatening complications after BKPro implantation, a longer follow-up period should provide outcomes that are more realistic. In this review, the authors examined only the results of publications with an average of at least 2 years of follow-up. The overall intermediate to long-term visual outcomes and retention rate in BKPro seem to be favorable. However, autoimmune diseases and cicatrizing conditions continue to show a higher incidence of postoperative complications that require further management.Keywords: Boston keratoprosthesis, corneal transplantation, limbal stem cell deficiencyNonpassopon MNiparugs MCortina MSDove Medical Pressarticleboston keratoprosthesiscorneal transplantationlimbal stem cell deficiencyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 14, Pp 1189-1200 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	boston keratoprosthesis corneal transplantation limbal stem cell deficiency Ophthalmology RE1-994
spellingShingle	boston keratoprosthesis corneal transplantation limbal stem cell deficiency Ophthalmology RE1-994 Nonpassopon M Niparugs M Cortina MS Boston Type 1 Keratoprosthesis: Updated Perspectives
description	Manachai Nonpassopon,1,2 Muanploy Niparugs,2,3 Maria Soledad Cortina2 1Department of Ophthalmology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; 3Department of Ophthalmology, Faculty of Medicine, Chaing Mai University, Chaing Mai, ThailandCorrespondence: Maria Soledad CortinaDepartment of Ophthalmology and Visual Sciences, University of Illinois at Chicago, 1855 W. Taylor Street, M/C 648, Chicago, IL 60612, USATel +1 312 996-6590Email mcortina@uic.eduAbstract: The use of Boston type 1 keratoprosthesis (BKPro) has significantly increased worldwide. It is no longer considered a procedure of last resort but a reasonable option for patients with otherwise poor prognosis for a traditional penetrating keratoplasty. BKPro was approved by the Food and Drug Administration in 1992 for bilateral severe corneal blindness due to multiple corneal transplant failure. Over the years, indications have extended beyond recurrent immunologic rejection to include other conditions such as chemical injury and other causes of bilateral limbal stem cell deficiency, extensive corneal neovascularization, neurotrophic corneas and hypotony, among others. Numerous advances in the design of the BKPro, improvement of preoperative, intraoperative and postoperative management have resulted in favorable outcomes and a reduction in postoperative complications. Accordingly, many studies have shown that implantation of this device is highly effective in restoring vision with very good short-term outcomes. However, due to the lifetime risk of sight-threatening complications after BKPro implantation, a longer follow-up period should provide outcomes that are more realistic. In this review, the authors examined only the results of publications with an average of at least 2 years of follow-up. The overall intermediate to long-term visual outcomes and retention rate in BKPro seem to be favorable. However, autoimmune diseases and cicatrizing conditions continue to show a higher incidence of postoperative complications that require further management.Keywords: Boston keratoprosthesis, corneal transplantation, limbal stem cell deficiency
format	article
author	Nonpassopon M Niparugs M Cortina MS
author_facet	Nonpassopon M Niparugs M Cortina MS
author_sort	Nonpassopon M
title	Boston Type 1 Keratoprosthesis: Updated Perspectives
title_short	Boston Type 1 Keratoprosthesis: Updated Perspectives
title_full	Boston Type 1 Keratoprosthesis: Updated Perspectives
title_fullStr	Boston Type 1 Keratoprosthesis: Updated Perspectives
title_full_unstemmed	Boston Type 1 Keratoprosthesis: Updated Perspectives
title_sort	boston type 1 keratoprosthesis: updated perspectives
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/d5857e8813e6450bbcef3a045b39cf13
work_keys_str_mv	AT nonpassoponm bostontype1keratoprosthesisupdatedperspectives AT niparugsm bostontype1keratoprosthesisupdatedperspectives AT cortinams bostontype1keratoprosthesisupdatedperspectives
_version_	1718397972408958976

Boston Type 1 Keratoprosthesis: Updated Perspectives

Ejemplares similares